Ophthalmic Comprehensive Reports

2025 Cataract Pharmaceuticals Market Report: Analysis of United States and Western Europe for 2024 to 2030, January, 2026

The new “2025 Cataract Pharmaceuticals Market Report” features newly updated data for both the United States and Western Europe, with expanded analysis of surgeon preferences for infection prevention, pupil dilation, and management of inflammation and pain. This year’s report provides deeper insight into the growing adoption of intracameral injections and fixed-combination eye drops, along with a clearer view of how branded, generic, and compounded products are being positioned in clinical practice. 

New analysis segments pharmaceutical usage by provider surgical volume, revealing meaningful differences in protocol selection and product mix. The report also includes updated five-year forecasts, expanded coverage of drug and drug-delivery pipelines, and refreshed market share analysis of leading companies to better capture the competitive landscape and where it is heading. 

The “2025 Cataract Pharmaceuticals Market Report” provides a comprehensive, data-driven market analysis of the drugs used before, during, and after cataract surgery in the United States and Western Europe. The report examines current utilization patterns and provides five-year forecasts for revenue by product category. 

Coverage includes antibiotics, anti-inflammatory agents, mydriatics/cycloplegics, pain management drugs, and intracameral formulations, along with a detailed look at fixed combinations, branded products, generics, and compounded alternatives. The report also explores evolving surgical practices, the growing role of intracameral injections, reimbursement dynamics, and the competitive pipeline shaping the future of cataract pharmaceuticals.  

This report provides a focused, data-driven view of the cataract pharmaceuticals market in the United States and Western Europe, examining procedure volumes, drug utilization patterns, competitive dynamics, and the evolving role of intracameral and combination therapies. The report covers drugs used at every stage of the cataract surgery process and connects clinical practice trends with market performance, pricing pressure, and pipeline innovation to deliver a clear picture of where the market stands today—and how it is expected to evolve over the next five years. 

  • Cataract incidence and surgical volumes: trends and market drivers in the US and Western Europe 
  • Procedure volume forecasts: five-year outlook for cataract surgery and lens-based procedures 
  • Phakic IOL and RLE trends: evolving role in refractive cataract care 
  • Antibiotic utilization and sales: perioperative usage patterns and revenue forecasts 
  • Mydriatics and cycloplegics: usage trends and market outlook 
  • Anti-inflammatory and pain management drugs: category-level forecasts and demand drivers 
  • Intracameral injections and fixed combinations: adoption trends and competitive impact 
  • Branded, generic, and compounded products: competitive dynamics and pricing pressure 
  • Cataract and refractive surgeon profiles: prescribing behavior and practice characteristics 
  • Reimbursement and pricing environment: policy trends, pressure points, and implications 
  • Pipeline products and emerging therapies: innovations poised to reshape the market 

2 licensing types are available for this report:

  • The price of the single-user license is $5,500.
  • The price of the enterprise license is $8,250 (includes supplemental Excel file with all the tables and figures in the report, and report summary slides).

Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.

SINGLE USER LICENSE

  • The Single User License allows for the use of a report by a single user within one corporate location.
  • The report paper copy may not be reproduced (additional paper copies available for purchase).
  • Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
  • Only a single copy of the publication may be printed for internal use.
  • Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
  • Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

  • The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
  • Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
  • Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
  • Purchase price includes a printable PDF file of the report (purchasing organization may print multiple copies for use within the organization).
  • Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.

Pay by credit card or by invoice.

Related Reports

Want to Purchase the Full Report?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.